TRHH-herb pair prevents IL-1β-induced degeneration of endplate chondrocytes in vitro

doi:10.5246/jcps.2016.08.066

Journal of Chinese Pharmaceutical Sciences ›› 2016, Vol. 25 ›› Issue (8): 590-597.DOI: 10.5246/jcps.2016.08.066

• Original articles • Previous Articles Next Articles

TRHH-herb pair prevents IL-1β-induced degeneration of endplate chondrocytes in vitro

Kai Niu^1,2,4, Chenguang Li^2,3, Song Yuan¹, Lei Zhang², Qi Shi^3,4, Yongjun Wang^3,4, Weichao Zheng^2*

1. Second People’s Hospital of Zhoushan, Zhoushan 316000, China
2. Medical College, Anhui University of Science and Technology, Huainan 232001, China
3. Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
4. Institute of Spine, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Received:2015-09-21 Revised:2015-10-13 Online:2016-09-01 Published:2015-10-27
Contact: Tel./Fax: +86-0554-6668808, +86-0580-2363011, E-mail: nk342896716@126.com, wzheng@aust.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 81273777, 81102606, 81072831), the National Basic Research Program of China (Grant No. 2010CB530400), the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT, IRT1270).

Abstract

Abstract:

The inflammatory cytokine interleukin-1 beta (IL-1β) plays a key role in the process of intervertebral disc degeneration (IVDD). In the present study, we aimed to evaluate the effect of pharmaco-serum of "Taoren-Honghua-herb pair" on IL-1β-induced chondrocyte degeneration in vitro. Taoren (Semen persicae) and Honghua (Safflower carthamus) were administered to the rats, and the pharmaco-serum was collected and prepared. Chondrocytes of the third passage, isolated from the rat’s vertebral endplates, were treated by standard medium only (Group NC), IL-1β (Group IL) or combination of IL-1β and pharmaco-serum (Group TRHH). Cell proliferation and apoptosis were determined, and the expression of aggrecan, Col2α1, Col10α1, IL-6 and SOX9 at the mRNA level in chondrocytes was quantified by real-time PCR. Immunohistochemistry staining of type II and X collagen and Safranine O staining were also used to evaluate the chondrocytes. Compared with the Group NC, IL-1β treatment inhibited the cell proliferation and induced the cell apoptosis (P<0.05), and the expression of aggrecan, Col2α1 and SOX9 at the mRNA level was down-regulated. In contrast, the expression of Col10α1 and IL-6 was up-regulated after IL-1β treatment (P<0.05). Meanwhile, the immune-staining of type II collagen and Safranine O staining were decreased, while the staining of type X collagen was increased. Compared with the Group IL, cell proliferation was increased, and apoptosis of chondrocytes was decreased when cells were treated with the pharmaco-serum of TRHH-herb pair (P<0.05). The expression of aggrecan, Col2α1 and SOX9 at the mRNA level was up-regulated, while that of Col10α1 and IL-6 was down-regulated (P<0.05). Safranine O staining also showed increased positive staining (P<0.05). Taken together, the treatment of pharmaco-serum of TRHH-herb pair could prevent endplate chondrocyte degeneration induced by IL-1β.

Key words: Pharmaco-serum, TRHH-herb pair, Degeneration, Chondrocyte, Intervertebral discs

CLC Number:

R962.1

Supporting:

Kai Niu, Chenguang Li, Song Yuan, Lei Zhang, Qi Shi, Yongjun Wang, Weichao Zheng. TRHH-herb pair prevents IL-1β-induced degeneration of endplate chondrocytes in vitro[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 590-597.

References

[1] Shim, J.M. Global Health. 2015, 11, 17.
[2] Siivola, S.M.; Levoska, S.T. Eur. Spine. J. 2002, 11, 358-363.
[3] Binder, A.I. B. M. J. 2007, 334, 527-531.
[4] Rutges, J.P.; Nikkels, P.G.; Oner, F.C. Eur. Spine. J. 2010, 19, 1340-1346.
[5] Cui, L.Y.; Liu, S.L; Ding, Y. Acta Pharmacol. Sin. 2007, 28, 1671-1676.
[6] Kang, J.D.; Georgescu, H.I.; McIntyre-Larkin, L. Spine (Phila Pa 1976). 1996, 21, 271-277.
[7] Saal, J.S.; Franson, R.C.; Dobrow, R. Spine (Phila Pa 1976). 1990, 15, 674-678.
[8] Yao, Y.M.; Mu, J.; Sun, J.; Yin, L.; Chen, J.; Lu, H.Z.; Zhang, L.J.J. Chin. Pharm. Sci. 2014, 23, 28-32.
[9] Kang, J.D.; Stefanovic-Racic, M.; Mclntyre, L.A. Spine (Phila Pa 1976). 1997, 22, 1065-1073.
[10] Le Maitre, C.L.; Freemont, A.J.; Hoyland, J.A. Arthritis Res. Ther. 2005, 7, 732-745.
[11] Wang, R.F.; Fan, L.G.; Gao, W.Y. Drugs Clinic. 2010, 25, 426-429.
[12] Mezzomo, N.; Mileo, B.R.; Friedrich, M.T. Bioresour Technol. 2010, 101, 5622-5632.
[13] Sánchez-Vicente, Y. J. Supercrit. Fluid. 2009, 49, 167-173.
[14] Mezzomo, N.; Martínez, J.; Ferreira, S.R.S. J. Supercrit. Fluid. 2009, 51, 10-16.
[15] Zhang, Y.; Zheng, W.C. Jiangsu J. Tradit. Chin. Med. 2010, 42, 77-79.
[16] Chen, M.; Zhao, P.W.; Sun, Y.L. Global Tradit. Chin. Med. 2012, 5, 556-560.
[17] Qi, Y.; Qin, W.Y.; Song, D.F. Pharm. Clin. Chin. Mater. Med. 2012, 28, 21-23.
[18] Shi, X.Y. Modern medical experimental animal science. Beijing: People’s Medical Officer Press, 2000, 332-338.
[19] Zhang, M.; Zhou, Q.; Liang, Q.Q. Osteoarthritis Cartilage. 2009, 17, 100-106.
[20] Buser, Z.; Kuelling, F.; Liu, J. Spine (Phila Pa 1976). 2011, 36, E1201-1209.
[21] Hoyland, J.A.; Le Maitre, C.; Freemont, A.J. Rheumatology (Oxford). 2008, 47, 809-814.
[22] Haupt, W.; Fritzsche, H.H. Eur. J. Surg. 1996, 162, 769-776.
[23] Cui, X.; Trinh, K.; Wang, Y.J. Cochrane Database Syst. Rev. 2010, CD006556.
[24] Zhang, Y.; Zhao, Y.J.; Zhou, Q. Immunol. J. 2012, 28, 665-668.
[25] Zhang, Y.; Zhao, Y.J.; Zhou, Q. Chin. Pharm. Bull. 2011, 27, 1704-1709.
[26] Goldring, M.B.; Birkhead, J.; Sandell, L.J. J. Clin. Invest. 1988, 82, 2026-2037.
[27] Takigawa, Y.; Hata, K.; Muramatsu, S. J. Cell Sci. 2010, 123, 3780-3788.
[28] Mwale, F.; Yao, G.; Ouellet, J.A. Tissue Eng. Part A. 2010, 16, 3449-3455.
[29] Omlor, G.W.; Nerlich, A.G.; Lorenz, H. Eur. Spine. J. 2012, 21, 1700-1708.
[30] Haudenschild, D.R.; Chen, J.; Pang, N. Arthritis Rheum. 2010, 62, 191-200.
[31] Cucchiarini, M.; Thurn, T.; Weimer, A. Arthritis Rheum. 2007, 56, 158-167.
[32] Liang, Q.Q.; Zhang, M.; Zhou, Q. Clin. Orthop. Relat. Res. 2010, 468, 1600-1610.
[33] Dai, L.; Zhang, X.; Hu, X. Arthritis Res. Ther. 2012, 14, R268.
[34] Studer, R.K.; Vo, N.; Sowa, G. Spine (Phila Pa 1976). 2011, 36, 593-599.
[35] Hu, L.L.; Tang, J.L.; Zhou, S.W. J. Chin. Pharm. Sci. 2015, 24, 393-399.
[36] Jimbo, K.; Park, J.S.; Yokosuka, K. J. Neurosurg. Spine. 2005, 2, 589-595.
[37] Rolf, T.; Axel, E. Front Pharmacol. 2015, 6, 72.
[38] Nicholas. E.; Kevin, D.; Denis, C. Pharmaceuticals (Basel). 2015, 8, 637-663.

TRHH-herb pair prevents IL-1β-induced degeneration of endplate chondrocytes in vitro

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	Daiying Zhou, Jing Chen, Zhigang Lv. Network pharmacology prediction and molecular docking-based study on the mechanism of Erigeron breviscapus in the treatment of age-related macular degeneratio [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 923-934.
[2]	Yadav Rakesh, Maan Monika, Yadav Divya. Synthesis and characterization of pyrimidines analogues as anti-Alzheimer’s agents [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 834-846.